Carolinas Healthcare System Union
- Type
- Teaching hospital
- Where
- Monroe, NC
- Medicare CCN
- 340130
- Received
- $3,825,910 in 335 records, 2020 ($17,353 general, $3,808,556 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 14 | $17,353 |
| 2020 | Research payment | 321 | $3,808,556 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Janssen Research & Development, LLC | 51 | $1,937,475 | 2020 |
| AstraZeneca Pharmaceuticals LP | 12 | $444,624 | 2020 |
| ABBVIE INC. | 71 | $313,153 | 2020 |
| Intercept Pharmaceuticals, Inc. | 40 | $309,523 | 2020 |
| Regeneron Pharmaceuticals, Inc. | 2 | $154,474 | 2020 |
| Celgene Corporation | 4 | $126,163 | 2020 |
| Eli Lilly and Company | 8 | $100,114 | 2020 |
| Alexion Pharmaceuticals, Inc. | 29 | $90,563 | 2020 |
| AstraZeneca UK Limited | 1 | $53,067 | 2020 |
| Arthrex, Inc. | 2 | $46,208 | 2020 |
| Janssen Scientific Affairs, LLC | 2 | $45,469 | 2020 |
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $41,552 | 2020 |
| Orion Corporation | 10 | $36,764 | 2020 |
| GENZYME CORPORATION | 11 | $25,791 | 2020 |
| Astellas Pharma Global Development | 2 | $22,509 | 2020 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $15,754 | 2020 |
| Stryker Corporation | 9 | $11,303 | 2020 |
| BIOTRONIK INC. | 30 | $10,512 | 2020 |
| Ethicon Endo-Surgery Inc. | 2 | $9,400 | 2020 |
| PFIZER INC. | 11 | $7,060 | 2020 |
| Tanabe Pharma America, Inc. | 1 | $6,500 | 2020 |
| SANOFI US SERVICES INC. | 12 | $5,800 | 2020 |
| Silk Road Medical, Inc. | 2 | $5,400 | 2020 |
| Penumbra, Inc. | 1 | $3,650 | 2020 |
| Allergan, Inc. | 4 | $3,075 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 321 | $3,808,556 |
| Space rental or facility fees (teaching hospital only) | 13 | $17,289 |
| Gift | 1 | $64 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $1,294 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati | 2020 |
| 2020-12-31 | Allergan, Inc. | $990 | Research payment | In-kind items and services | A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamoreli | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $851 | Research payment | In-kind items and services | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2020 | |
| 2020-12-31 | Stryker Corporation | $64 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-30 | ABBVIE INC. | $5,651 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-12-30 | Penumbra, Inc. | $3,650 | Research payment | Cash or cash equivalent | Indigo Device, Peripheral Intervention | STRIDE | 2020 |
| 2020-12-30 | ABBVIE INC. | $161 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-654 | 2020 |
| 2020-12-29 | AstraZeneca Pharmaceuticals LP | $9,170 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase IB, Open-Label, Randomized, Multi-Center Platform Study to Determine the Efficacy and Safety of Durvalumab (MEDI | 2020 |
| 2020-12-24 | Regeneron Pharmaceuticals, Inc. | $99,745 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-12-23 | Intercept Pharmaceuticals, Inc. | $14,434 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-23 | Intercept Pharmaceuticals, Inc. | $11,307 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-12-23 | Intercept Pharmaceuticals, Inc. | $1,654 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-12-21 | AstraZeneca Pharmaceuticals LP | $178,559 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | Title not available in IMPACT or MLCS | 2020 |
| 2020-12-18 | Janssen Research & Development, LLC | $99,556 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2020 | |
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-17 | Alexion Pharmaceuticals, Inc. | $520 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-12-16 | Intercept Pharmaceuticals, Inc. | $3,000 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-16 | Alexion Pharmaceuticals, Inc. | $260 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-12-15 | Orion Corporation | $700 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension (REFALS-ES) | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $25,174 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With R | 2020 | |
| 2020-12-10 | AstraZeneca Pharmaceuticals LP | $149,787 | Research payment | Cash or cash equivalent | Quality Improvement by Implementing Utilizing and Assessing Evidence Based Pathways for Stage III and IV NSCLC in a Regi | 2020 | |
| 2020-12-08 | Alexion Pharmaceuticals, Inc. | $8,958 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-12-08 | ABBVIE INC. | $6,379 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-654 | 2020 |
| 2020-12-08 | Orion Corporation | $505 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | 2020 | |
| 2020-12-07 | ABBVIE INC. | $1,518 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-12-04 | ABBVIE INC. | $1,642 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-430 | 2020 |
| 2020-12-03 | ABBVIE INC. | $2,860 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-430 | 2020 |
| 2020-12-03 | Janssen Research & Development, LLC | $2,324 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-12-03 | ABBVIE INC. | $1,180 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-12-03 | ABBVIE INC. | $885 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-12-02 | ABBVIE INC. | $1,677 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-066 | 2020 |
| 2020-11-27 | Janssen Research & Development, LLC | $21,000 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2020 | |
| 2020-11-27 | Eli Lilly and Company | $2,270 | Research payment | Cash or cash equivalent | A PHASE 1B STUDY OF LY2835219 IN COMBINATION WITH MULTIPLE SINGLE AGENT OPTIONS FOR PATIENTS WITH STAGE IV NSCLC | 2020 | |
| 2020-11-23 | Janssen Research & Development, LLC | $142,599 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2020 | |
| 2020-11-23 | Janssen Research & Development, LLC | $3,950 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Del | 2020 | |
| 2020-11-23 | GENZYME CORPORATION | $53 | Research payment | Cash or cash equivalent | LEMTRADA Biological, Neurology | A Prospective 24-Month Observational Study of Neurocognitive Function and Safety in Patients with Relapsing Multiple Scl | 2020 |
| 2020-11-20 | Janssen Research & Development, LLC | $12,470 | Research payment | Cash or cash equivalent | A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283 | 2020 | |
| 2020-11-20 | Ethicon Endo-Surgery Inc. | $3,400 | Research payment | Cash or cash equivalent | ECHELON FLEX Stapler Device, Endo-Mechanical | Evaluation of Staple Line Effectiveness in Distal Pancreatectomy: An Ex Vivo Human Tissue Study ETH-2017-03 - Dr. Iannit | 2020 |
| 2020-11-18 | Intercept Pharmaceuticals, Inc. | $10,754 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-11-18 | Intercept Pharmaceuticals, Inc. | $1,616 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-11-17 | AstraZeneca Pharmaceuticals LP | $36,334 | Research payment | Cash or cash equivalent | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2020 | |
| 2020-11-16 | Janssen Scientific Affairs, LLC | $40,884 | Research payment | Cash or cash equivalent | INVEGA SUSTENNA Drug, Neuroscience | Impact of paliperidone palmitate on clinical, economic, and psychosocial outcomes in patients with schizophrenia from a | 2020 |
| 2020-11-12 | Janssen Research & Development, LLC | $11,000 | Research payment | Cash or cash equivalent | A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283 | 2020 | |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-11 | Alexion Pharmaceuticals, Inc. | $4,300 | Research payment | Cash or cash equivalent | A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab | 2020 | |
| 2020-11-05 | Janssen Research & Development, LLC | $866 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk | 2020 | |
| 2020-11-04 | Stryker Corporation | $4,741 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MAKO Device, KNEES, HIPS | 2020 | |
| 2020-11-02 | Eli Lilly and Company | $28,995 | Research payment | Cash or cash equivalent | PHASE 1B STUDY OF LY3295668 ERBUMINE MONOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE, EXTENSIVE-STAGE SMALL-CELL LUNG CA | 2020 | |
| 2020-11-02 | Janssen Scientific Affairs, LLC | $4,585 | Research payment | Cash or cash equivalent | INVEGA SUSTENNA Drug, Neuroscience | Impact of paliperidone palmitate on clinical, economic, and psychosocial outcomes in patients with schizophrenia from a | 2020 |
| 2020-11-02 | Janssen Research & Development, LLC | $194 | Research payment | Cash or cash equivalent | Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myel | 2020 | |
| 2020-10-29 | ABBVIE INC. | $56 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-433 | 2020 |
| 2020-10-28 | Intercept Pharmaceuticals, Inc. | $11,975 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-10-28 | Intercept Pharmaceuticals, Inc. | $10,223 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-10-26 | Janssen Research & Development, LLC | $208,139 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2020 | |
| 2020-10-26 | Janssen Research & Development, LLC | $3,527 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $2,079 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome | 2020 | |
| 2020-10-23 | Stryker Corporation | $3,042 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MAKO Device, KNEES, HIPS | 2020 | |
| 2020-10-23 | Stryker Corporation | $1,185 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TRIDENT Device, HIPS | 2020 | |
| 2020-10-23 | Stryker Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ACCOLADE Device, HIPS | 2020 | |
| 2020-10-23 | Stryker Corporation | $390 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TRIDENT Device, HIPS | 2020 | |
| 2020-10-23 | Stryker Corporation | $390 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ACCOLADE Device, HIPS | 2020 | |
| 2020-10-23 | Stryker Corporation | $280 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ACCOLADE Device, HIPS | 2020 | |
| 2020-10-23 | Stryker Corporation | $210 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ACCOLADE Device, HIPS | 2020 | |
| 2020-10-22 | Janssen Research & Development, LLC | $1,179 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subject | 2020 | |
| 2020-10-21 | Intercept Pharmaceuticals, Inc. | $14,410 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-10-21 | ABBVIE INC. | $1,333 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-066 | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $276 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $276 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $276 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $274 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $274 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $274 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $274 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $217 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $217 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $217 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $217 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $104 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $104 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $104 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $20 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-08 | Janssen Research & Development, LLC | $866 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk | 2020 | |
| 2020-10-07 | Intercept Pharmaceuticals, Inc. | $3,000 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-10-01 | Janssen Research & Development, LLC | $1,162 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-09-30 | ABBVIE INC. | $3,954 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-654 | 2020 |
| 2020-09-30 | ABBVIE INC. | $2,928 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-09-30 | ABBVIE INC. | $2,866 | Research payment | Cash or cash equivalent | M14-222 | 2020 | |
| 2020-09-21 | Janssen Research & Development, LLC | $111,891 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2020 | |
| 2020-09-16 | Intercept Pharmaceuticals, Inc. | $11,282 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-09-16 | Intercept Pharmaceuticals, Inc. | $8,526 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-09-16 | Intercept Pharmaceuticals, Inc. | $2,300 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-09-16 | Alexion Pharmaceuticals, Inc. | $780 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-10 | Takeda Pharmaceuticals U.S.A., Inc. | $425 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2020 | |
| 2020-09-09 | Alexion Pharmaceuticals, Inc. | $9,081 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-09 | ABBVIE INC. | $8,547 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-09-09 | Alexion Pharmaceuticals, Inc. | $3,470 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-09 | Alexion Pharmaceuticals, Inc. | $3,076 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-09 | Alexion Pharmaceuticals, Inc. | $1,839 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-09 | Alexion Pharmaceuticals, Inc. | $1,785 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-09 | Alexion Pharmaceuticals, Inc. | $1,145 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-09 | Alexion Pharmaceuticals, Inc. | $1,137 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-09 | Alexion Pharmaceuticals, Inc. | $650 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-09 | Alexion Pharmaceuticals, Inc. | $585 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-09 | Alexion Pharmaceuticals, Inc. | $520 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-04 | Janssen Research & Development, LLC | $18,278 | Research payment | Cash or cash equivalent | A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or | 2020 | |
| 2020-09-03 | Regeneron Pharmaceuticals, Inc. | $54,729 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY OF REGN4659 (ANTI-CTLA-4 MAB) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 MAB) IN THE TREATMENT OF PATIENT | 2020 | |
| 2020-09-01 | ABBVIE INC. | $2,893 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-654 | 2020 |
| 2020-08-31 | Janssen Research & Development, LLC | $959 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk | 2020 | |
| 2020-08-31 | ABBVIE INC. | $40 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-08-28 | Janssen Research & Development, LLC | $2,365 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-08-26 | Intercept Pharmaceuticals, Inc. | $1,714 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-08-26 | Intercept Pharmaceuticals, Inc. | $1,143 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-08-26 | Alexion Pharmaceuticals, Inc. | $45 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-08-25 | Alexion Pharmaceuticals, Inc. | $2,079 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome | 2020 | |
| 2020-08-24 | Janssen Research & Development, LLC | $243,469 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2020 | |
| 2020-08-24 | Janssen Research & Development, LLC | $19,448 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subject | 2020 | |
| 2020-08-20 | ABBVIE INC. | $5,440 | Research payment | Cash or cash equivalent | M13-576 | 2020 | |
| 2020-08-20 | ABBVIE INC. | $1,175 | Research payment | Cash or cash equivalent | M13-576 | 2020 | |
| 2020-08-20 | Eli Lilly and Company | $169 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2020 | |
| 2020-08-19 | Intercept Pharmaceuticals, Inc. | $800 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-08-17 | GENZYME CORPORATION | $525 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-08-17 | GENZYME CORPORATION | $50 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2020 | |
| 2020-08-17 | GENZYME CORPORATION | $25 | Research payment | Cash or cash equivalent | Gaucher LSD Data Registry | 2020 | |
| 2020-08-13 | ABBVIE INC. | $998 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-430 | 2020 |
| 2020-08-12 | Intercept Pharmaceuticals, Inc. | $26,148 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-08-12 | Intercept Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-08-11 | Orion Corporation | $4,908 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension (REFALS-ES) | 2020 | |
| 2020-08-04 | ABBVIE INC. | $2,558 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-08-03 | ABBVIE INC. | $1,677 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-066 | 2020 |
| 2020-07-31 | ABBVIE INC. | $1,983 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-654 | 2020 |
| 2020-07-30 | Janssen Research & Development, LLC | $3,527 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-07-30 | Janssen Research & Development, LLC | $2,564 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk | 2020 | |
| 2020-07-29 | Takeda Pharmaceuticals U.S.A., Inc. | $10,330 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2020 | |
| 2020-07-29 | Intercept Pharmaceuticals, Inc. | $7,867 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-07-29 | Intercept Pharmaceuticals, Inc. | $7,567 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-07-29 | Intercept Pharmaceuticals, Inc. | $2,565 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-07-28 | Orion Corporation | $600 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension (REFALS-ES) | 2020 | |
| 2020-07-27 | Janssen Research & Development, LLC | $16,955 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2020 | |
| 2020-07-24 | Bayer Healthcare Pharmaceuticals Inc. | $6,070 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-07-24 | Bayer Healthcare Pharmaceuticals Inc. | $1,990 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-07-24 | Bayer Healthcare Pharmaceuticals Inc. | $1,930 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-07-24 | Bayer Healthcare Pharmaceuticals Inc. | $1,885 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-07-24 | Bayer Healthcare Pharmaceuticals Inc. | $1,595 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-07-24 | Bayer Healthcare Pharmaceuticals Inc. | $590 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-07-24 | Bayer Healthcare Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2020 |
| 2020-07-23 | Janssen Research & Development, LLC | $136,373 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subject | 2020 | |
| 2020-07-23 | Alexion Pharmaceuticals, Inc. | $9,000 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-07-23 | Alexion Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-07-23 | Eli Lilly and Company | $626 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2020 | |
| 2020-07-22 | Alexion Pharmaceuticals, Inc. | $14,625 | Research payment | Cash or cash equivalent | A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab | 2020 | |
| 2020-07-21 | Orion Corporation | $5,400 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | 2020 | |
| 2020-07-16 | Janssen Research & Development, LLC | $18,214 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With R | 2020 | |
| 2020-07-16 | Janssen Research & Development, LLC | $12,485 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With R | 2020 | |
| 2020-07-16 | Takeda Pharmaceuticals U.S.A., Inc. | $425 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2020 | |
| 2020-07-09 | Ethicon Endo-Surgery Inc. | $6,000 | Research payment | Cash or cash equivalent | ECHELON FLEX Stapler Device, Endo-Mechanical | Evaluation of Staple Line Effectiveness in Distal Pancreatectomy: An Ex Vivo Human Tissue Study ETH-2017-03 - Dr. Iannit | 2020 |
| 2020-07-08 | Intercept Pharmaceuticals, Inc. | $40,404 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-07-08 | Intercept Pharmaceuticals, Inc. | $4,547 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-07-07 | Orion Corporation | $600 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension (REFALS-ES) | 2020 | |
| 2020-07-06 | ABBVIE INC. | $6,927 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-07-03 | Janssen Research & Development, LLC | $12,233 | Research payment | Cash or cash equivalent | Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Sub | 2020 | |
| 2020-07-02 | Janssen Research & Development, LLC | $76,595 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2020 | |
| 2020-07-02 | Janssen Research & Development, LLC | $2,275 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk | 2020 | |
| 2020-07-01 | ABBVIE INC. | $1,801 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-430 | 2020 |
| 2020-07-01 | ABBVIE INC. | $471 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-433 | 2020 |
| 2020-06-30 | ABBVIE INC. | $6,223 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-654 | 2020 |
| 2020-06-30 | ABBVIE INC. | $413 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-06-29 | Janssen Research & Development, LLC | $94,843 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2020 | |
| 2020-06-28 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-06-25 | Janssen Research & Development, LLC | $11,698 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2020 | |
| 2020-06-25 | Janssen Research & Development, LLC | $1,203 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-06-24 | ABBVIE INC. | $30,001 | Research payment | Cash or cash equivalent | M16-534 | 2020 | |
| 2020-06-24 | Intercept Pharmaceuticals, Inc. | $17,310 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-06-24 | Takeda Pharmaceuticals U.S.A., Inc. | $1,158 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2020 | |
| 2020-06-22 | Alexion Pharmaceuticals, Inc. | $2,286 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome | 2020 | |
| 2020-06-22 | ABBVIE INC. | $1,329 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-066 | 2020 |
| 2020-06-15 | SANOFI US SERVICES INC. | $400 | Research payment | Cash or cash equivalent | KEVZARA Biological, Immunology | GMA LRP PLACEHOLDER - Prospective product registry- PROFILE | 2020 |
| 2020-06-10 | Intercept Pharmaceuticals, Inc. | $3,249 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1009742 | 2020 |
| 2020-06-10 | Intercept Pharmaceuticals, Inc. | $53 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1009742 | 2020 |
| 2020-06-02 | Janssen Research & Development, LLC | $9,969 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subject | 2020 | |
| 2020-06-02 | Janssen Research & Development, LLC | $3,527 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-05-31 | AstraZeneca UK Limited | $53,067 | Research payment | Cash or cash equivalent | A Phase I/II Open-Label Multicentre 2-Part Study to Assess the Safety Tolerability Pharmacokinetics and Efficacy of AZD2 | 2020 | |
| 2020-05-31 | Tanabe Pharma America, Inc. | $6,500 | Research payment | Cash or cash equivalent | RADICAVA Drug, AMYOTROPHIC LATERAL SCLEROSIS | RADICAVA (EDAVARONE) FINDINGS IN BIOMARKERS FROM ALS (REFINE-ALS) | 2020 |
| 2020-05-29 | ABBVIE INC. | $6,973 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-654 | 2020 |
| 2020-05-29 | ABBVIE INC. | $1,264 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-05-28 | ABBVIE INC. | $9,360 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-433 | 2020 |
| 2020-05-28 | ABBVIE INC. | $1,687 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-430 | 2020 |
The latest 200 records of 335.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Monroe, NC, county Union County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Monroe, NC | County Union County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 36,759 | 250,958 | 10,730,404 |
| Population, 2020 census P1 | 34,562 | 238,267 | 10,439,388 |
| Median age B01002 | 35.5 | 39.2 | 39.1 |
| Under 18 B01001 | 24.5% | 25.6% | 21.8% |
| 65 and over B01001 | 14.9% | 13.5% | 17.2% |
| Households B11001 | 12,620 | 84,237 | 4,282,345 |
| Foreign born B05002 | 17.8% | 12.2% | 9.1% |
| Median household income B19013 | $72,540 | $102,900 | $72,388 |
| Median family income B19113 | $80,817 | $118,218 | $90,290 |
| Per capita income B19301 | $31,089 | $46,949 | $41,385 |
| Poverty rate B17001 | 13.3% | 7.7% | 13.0% |
| Unemployment rate B23025 | 4.6% | 4.2% | 4.7% |
| Civilian labor force B23025 | 18,613 | 132,592 | 5,336,863 |
| Mean commute (minutes) B08013 | 30.1 | 29.8 | 25.1 |
| Bachelor's degree or higher B15003 | 24.1% | 40.5% | 35.7% |
| Housing units B25001 | 13,469 | 88,851 | 4,895,668 |
| Owner-occupied B25003 | 61.6% | 81.6% | 66.6% |
| Renters B25003 | 38.4% | 18.4% | 33.4% |
| Median home value B25077 | $309,100 | $417,300 | $288,900 |
| Median gross rent B25064 | $1,246 | $1,496 | $1,228 |
| White, not Hispanic B03002 | 43.7% | 66.8% | 60.0% |
| Black B03002 | 19.7% | 10.9% | 20.0% |
| Hispanic or Latino B03002 | 30.9% | 13.4% | 11.3% |
| Asian B03002 | 1.0% | 4.5% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Monroe, NC.
Comments